Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04211337
Title	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Acronym	LIBRETTO-531
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Eli Lilly and Company
Indications	thyroid gland medullary carcinoma
Therapies	Vandetanib Cabozantinib Selpercatinib
Age Groups:	adult \| senior \| child
Covered Countries	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS